Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF -2-
February 26, 2001
- Sysmex Expands Its Development Base in Europe
February 26, 2001
- Chuikyo Subcommittee Starts Discussions on Drug Prices
February 26, 2001
- Reorganization to Push New Drugs into Orbit as Soon as Possible: Mr Nakashima of Tanabe
February 26, 2001
- Healthcare Reform Proposals Expected No Sooner Than Fall
February 26, 2001
- Welfide Licenses Agent for Diabetic Neuropathy to Takeda
February 26, 2001
- Additional Indications Required to Commercialize Artificial Erythrocytes
February 26, 2001
- Fujisawa Launches Protopic in US
February 26, 2001
- Aventis Behring Launches Web Site
February 26, 2001
- Worldwide Sales of Yakult's Irinotecan to Top \150 Bil. in 2005
February 26, 2001
- Council Starts Discussions to Improve Drug Information Supply System
February 26, 2001
- Kyorin, Ono to Codevelop Drug for Urinary Incontinence
February 26, 2001
- METI Report Calls For Free Competition for Medical, Nursing Care Services
February 26, 2001
- BUSINESS NEWS IN BRIEF -1-
February 26, 2001
- Elimination of NHI Price SystemShould Be Considered: Prof. Tokita
February 26, 2001
- REGULATORY NEWS IN BRIEF
February 26, 2001
- WORLD BUSINESS NEWS IN BRIEF
February 26, 2001
- GSK Appeals to Tokyo High Court in Aciclovir Patent Dispute
February 19, 2001
- Merger of Medical, Nursing Care Insurance Programs Proposed: JMA Symposium
February 19, 2001
- About Half of Hospitals Reuse Single Use Devices
February 19, 2001
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…